Health Economics›Non-small cell lung cancer›Advanced or metastatic disease subsequent lines of therapy

Advanced or metastatic disease subsequent lines of therapy

Non-small cell lung cancer · 24 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

FiltersBiomarker

Y-axis

Cost vs Efficacy · 8 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Pembrolizumab monotherapy Variant #01	—	R 286 955	14d	—	11.6 mo	—	—	2
nab-Paclitaxel monotherapy Variant #01	—	R 45 710	28d	—	16.2 mo	—	—	1
Afatinib monotherapy Variant #01	—	R 34 727	28d	—	10.8 mo	—	—	1
Atezolizumab monotherapy Variant #01	—	R 31 255	21d	—	13.0 mo	—	—	2
Gemcitabine monotherapy Variant #20	—	R 14 213	56d	—	9.5 mo	—	—	1
Erlotinib monotherapy Variant #01	—	R 13 907	28d	1.8 mo	7.3 mo	2	R 27 814 PFS proxy	8
Docetaxel and Nintedanib Variant #01	—	R 9 375	21d	3.4 mo	10.1 mo	5	R 46 873 PFS proxy	2
Afatinib and Paclitaxel Variant #01	—	R 9 237	7d	5.6 mo	—	25	R 230 919 PFS proxy	1
Gefitinib monotherapy Variant #01	—	R 8 556	28d	3.4 mo	7.6 mo	4	R 34 222 PFS proxy	6
Docetaxel and Nivolumab Variant #01 Partial	—	R 1 656	28d	—	23.1 mo	—	—	1
Vinorelbine monotherapy Variant #01	—	R 583	21d	—	9.5 mo	—	—	1
Docetaxel monotherapy N/A - secondary systemic drug	—	R 243	28d	3.2 mo	9.8 mo	4	R 973 PFS proxy	39
Docetaxel monotherapy N/A - secondary systemic drug	MET	R 243	28d	3.2 mo	9.8 mo	4	R 973 PFS proxy	39
Docetaxel monotherapy N/A - secondary systemic drug	KRAS	R 243	28d	3.2 mo	9.8 mo	4	R 973 PFS proxy	39
Pemetrexed monotherapy N/A - secondary systemic drug	—	R 69	21d	2.9 mo	8.3 mo	5	R 347 PFS proxy	9
Icotinib monotherapy Variant #01 Partial	—	—	28d	4.6 mo	—	6	—	1
Placebo Partial	—	—	—	—	6.3 mo	—	—	5
Amrubicin monotherapy Variant #01 Partial	—	—	21d	3.6 mo	—	6	—	1
Nivolumab monotherapy Variant #01 Partial	—	—	14d	—	13.3 mo	—	—	2
Adagrasib monotherapy Variant #01 Partial	KRAS	—	28d	5.5 mo	—	6	—	1
Sotorasib monotherapy Variant #01 Partial	KRAS	—	28d	5.6 mo	—	7	—	1
Tislelizumab monotherapy Variant #01 Partial	—	—	21d	—	17.2 mo	—	—	1
S-1 monotherapy Variant #01 Partial	—	—	21d	—	12.8 mo	—	—	1
Best supportive care Partial	—	—	—	—	4.6 mo	—	—	1

24 of 24 regimens shown